March 20, 2024
(press release)
–
GSK today announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all of its asthma and chronic obstructive pulmonary disease (COPD) medicines,* the most prescribed portfolio of inhalers in the U.S. GSK is taking this action as part of its longstanding commitment to improving access to respiratory medicines in the U.S. and to help asthma and COPD patients who are least able to afford the care they need. The out-of-pocket price cap will provide a significant benefit to patients taking these medicines whose monthly costs currently exceed $35. Maya Martinez-Davis, President, U.S. Commercial, GSK said: “GSK is committed to bringing innovation and accessibility to patients with respiratory illnesses. In the U.S., we already provide significant rebates and discounts for our products, as well as patient assistance programs, to help bring down costs and this new commitment, combined with our existing offerings, will help even more patients living with asthma or COPD.” The program is wide reaching and will be implemented no later than January 1, 2025. The medicines in scope are: GSK will share specific details closer to implementation. Today’s announcement builds on GSK’s strong track record of increasing access and improving the affordability of its medicines, including an ongoing commitment to responsible pricing. GSK recently reduced the wholesale acquisition cost for Advair Diskus by an average of 50% and Advair HFA by an average of 20%. GSK offers patient assistance through multiple programs such as the GSK Patient Access Programs Foundation and the GSK Patient Assistance Program, which provides many medicines and vaccines at no cost to eligible patients in the U.S. (https://gskforyou.com). Refer to the Advair Diskus website for the Indication, Important Safety Information and Prescribing Information, including Patient Information, in the United States. Refer to the Advair HFA website for the Indication, Important Safety Information and Prescribing Information, including Patient Information, in the United States. Refer to the Anoro Ellipta website for the Indication, Important Safety Information and Prescribing Information, including Patient Information, in the United States. Refer to the Arnuity Ellipta website for the Indication, Important Safety Information and Prescribing Information, including Patient Information, in the United States. Refer to the Breo Ellipta website for the Indication, Important Safety Information and Prescribing Information, including Patient Information, in the United States. Refer to the Incruse Ellipta website for the Indication, Important Safety Information and Prescribing Information, including Patient Information, in the United States. Refer to the Serevent Diskus website for the Prescribing Information, including Medication Guide, in the United States. Refer to the Trelegy Ellipta website for the Indication, Important Safety Information and Prescribing Information, including Patient Information, in the United States. Refer to the Ventolin HFA website for the Indication, Important Safety Information and Prescribing Information, including Patient Information, in the United States. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com. About GSKForYou GSKforYou is a program committed to assisting eligible patients access our medications. We offer programs for patients who meet income and other eligibility requirements. Information regarding these programs is available on GSKforYou.com. *Terms and conditions apply. Government restrictions exclude people enrolled in federal government insurance programs from co-pay support.
IMPORTANT SAFETY INFORMATION
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in the company's Annual Report on Form 20-F for 2023.
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.
